Novo Says Wegovy Injection Lowers BMI and Obesity Rates in Children in Trial
The phase 3 trial found more than 40% of treated children no longer met obesity criteria after 68 weeks, with no growth or puberty safety concerns.
10 Articles
10 Articles
Novo has studied the effect of semaglutide, found in the weight loss drug Wegovy, in children aged 6 to 12 years.
Novo has studied the effect of semaglutide, found in the weight loss drug Wegovy, in children aged 6 to 12 years.
Wegovy® resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine
/PRNewswire/ -- Today, Novo Nordisk shared primary results from the phase 3 STEP Young trial evaluating the safety and efficacy of investigational once-weekly...
Should children under 12 be treated with weight loss medication? Novo has found benefits from treatment with the weight loss medication Wegovy, while the World Health Organization (WHO) is concerned.
Health: The Vegovi drug showed high efficiency in the treatment of obesity in children between 6 and 11 years of age; almost 80 per cent of the participants in the clinical study have reduced the IMT by at least 10 per cent.
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium










